Tarsus Pharmaceuticals Inc. (TARS) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Tarsus Pharmaceuticals In... (TARS)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

44.30

-2.72 (-5.78%)

At close: Jan 14, 2025, 3:59 PM

43.60

-1.58%

Pre-market Jan 15, 2025, 05:30 AM EST

undefined% (undefined)

Bid	41.54
Market Cap	1.69B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-3.75
PE Ratio (ttm)	-11.81
Forward PE	n/a
Analyst	Buy

Ask	57.4
Volume	763,636
Avg. Volume (20D)	765,540
Open	47.82
Previous Close	47.02
Day's Range	43.61 - 47.87
52-Week Range	20.08 - 57.14
Beta	undefined

About TARS

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; a...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Oct 16, 2020

Employees 244

Stock Exchange NASDAQ

Ticker Symbol TARS

Website https://www.tarsusrx.com

Analyst Forecast

According to 5 analyst ratings, the average rating for TARS stock is "Buy." The 12-month stock price forecast is $60, which is an increase of 35.44% from the latest price.

Buy 80.00%

Hold 20.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Tarsus Pharmaceuticals Inc. is scheduled to release its earnings on Feb 25, 2025, before market opens.
Analysts project revenue of $58.02M, reflecting a 343.71% YoY growth and earnings per share of -0.86, making a -34.35% decrease YoY.

Why Price Moved

2 months ago · Source

+0.3%

Tarsus Pharmaceuticals shares are trading higher a... Unlock content with Pro Subscription

2 months ago · Source

-2.23%

Tarsus Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results.

News

1 day ago · zacks.com

Down -9.11% in 4 Weeks, Here's Why Tarsus Pharmaceuticals (TARS) Looks Ripe for a Turnaround

The heavy selling pressure might have exhausted for Tarsus Pharmaceuticals (TARS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Str...

3 weeks ago · zacks.com

4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow

Here, we discuss four biotech stocks, ADMA, TARS, STOK and CDXC, which have returned more than 50% year to date and have room for more growth in 2025.

1 month ago · seekingalpha.com

Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's Top 2 Picks

Jonathan Faison runs the ROTY Biotech Community. Why he's high on Tarsus Pharmaceuticals and his #1 holding, SpringWorks Therapeutics.

1 month ago · zacks.com

Wall Street Analysts Think Tarsus Pharmaceuticals (TARS) Could Surge 26.98%: Read This Before Placing a Bet

The consensus price target hints at a 27% upside potential for Tarsus Pharmaceuticals (TARS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earni...

1 month ago · zacks.com

Wall Street Analysts Believe Tarsus Pharmaceuticals (TARS) Could Rally 41.09%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 41.1% in Tarsus Pharmaceuticals (TARS). While the effectiveness of this highly sought-after metric is questiona...

2 months ago · seekingalpha.com

Tarsus Pharmaceuticals, Inc. (TARS) Q3 2024 Earnings Call Transcript

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants David Nakasone - Head, IR Bobby Azamian - Chairman & CEO Aziz Mottiwala -...

2 months ago · zacks.com

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates

Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $1.28 per share a year ago.

2 months ago · zacks.com

Tarsus Pharmaceuticals, Inc. (TARS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Tarsus Pharmaceuticals (TARS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago · zacks.com

Tarsus Pharmaceuticals (TARS) Surges 10.6%: Is This an Indication of Further Gains?

Tarsus Pharmaceuticals (TARS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further streng...